Stock 1.) Traton - Commercial vehicle manufacturer suffers from weak market environment and tariff concerns, forecast downgrade leads to price drop! Significant declines were observed at Traton on Friday. The commercial vehicle manufacturer revised its annual forecast downwards last night after the market close due to weak developments in the US and...
Ranking of Long-Term Performer Stocks
Long-Run Stocks are steadily rising stocks that outperform the market. Identification utilizes 'stable price growth' and the 'Monkey-Trader' indicator, which measures stable price trends and ease of trading.
| Rank | Stock | Price | Mkt.- | Monkey- | Stable Pr. Growth | Ø Yr Perf. | Ø Drawdown |
|---|---|---|---|---|---|---|---|
| WKN | Symbol | |||||||
| 1 | Brown & Brown | 111.31 $ | 31.90 Mrd. | 88.50 % | 98.88 % | 21.06 % | -16.96 % |
| 896895 | BRO | |||||||
| 2 | Arthur J. Gallagher | 308.35 $ | 78.89 Mrd. | 87.06 % | 99.14 % | 20.24 % | -17.67 % |
| 869761 | AJG | |||||||
| 3 | Republic Services | 228.73 $ | 71.43 Mrd. | 86.62 % | 98.87 % | 19.25 % | -15.41 % |
| 915201 | RSG | |||||||
| 4 | Deutsche Börse | 253.80 € | 46.66 Mrd. | 91.93 % | 96.19 % | 15.14 % | -19.67 % |
| 581005 | DB1 | |||||||
| 5 | O'Reilly Automotive | 1,313.51 $ | 75.19 Mrd. | 87.19 % | 96.54 % | 21.46 % | -20.45 % |
| A1H5JY | ORLY | |||||||
| 6 | ExlService Holdings | 42.18 $ | 6.85 Mrd. | 89.15 % | 95.65 % | 22.29 % | -26.03 % |
| A0LB2A | EXLS | |||||||
| 7 | StoneX Group | 70.32 $ | 3.39 Mrd. | 91.20 % | 94.59 % | 24.54 % | -28.29 % |
| A2P8CE | SNEX | |||||||
| 8 | Broadridge Financial Solutions | 218.87 $ | 25.61 Mrd. | 87.57 % | 95.24 % | 17.45 % | -21.34 % |
| A0MMP1 | BR | |||||||
| 9 | Verisk Analytics | 278.09 $ | 38.92 Mrd. | 83.32 % | 96.94 % | 15.96 % | -19.59 % |
| A0YA2M | VRSK | |||||||
| 10 | Argenx | 479.70 € | 32.35 Mrd. | 86.59 % | 95.37 % | 50.79 % | -31.16 % |
| A11602 | 1AE | |||||||
Subscribe now to see the full ranking
Already a subscriber? Login
Sample Issue
$
0
one issue
Bestseller
Trial Subscription
$
33
1 month
Merck & Co (MRK) is currently one of the most exciting turnaround stories among the pharma big caps. After the pharmaceutical giant faced significant pressure due to the patent expiration for the oncology blockbuster Keytruda in 2028 and the announced drug price cuts by the U.S. administration, the negative news is likely already priced in. With...